جست‌وجوی استاد و پژوهشگر

• Haematology
• Genetics
• Haematological malignancy
• +۳ مورد دیگر

Professor Stephen Fuller is a Professor of Medicine and Head of Nepean Clinical School at the University of Sydney. He holds affiliations with the Brain and Mind Centre and Charles Perkins Centre. His research focuses on haematology, genetics of blood disorders, and purinergic receptor biology (P2X7/P2Y receptors). Key interests include chronic lymphocytic leukemia (CLL), sepsis pathogenesis, and inflammatory mechanisms. Education: MBBS, PhD, FRACP (Fellow of the Royal Australasian College of Physicians), FRCPA (Fellow of the Royal College of Pathologists of Australasia). Research highlights include genetic studies of CLL susceptibility, P2X7 receptor polymorphisms in sepsis outcomes, and cytokine signaling in immunological diseases. Recent work explores P2X7 receptor structure using AlphaFold2 and deep learning. Grants include Ion Channel Drug Discovery Consortium (2017), P2X7 Cancer Research (2016), and projects investigating familial haematological malignancies. Advises current PhD students researching B-cell receptor interactions, bariatric surgery pathways, and P2X7R in sepsis pathogenesis. Labs/teams: Leads research groups in Nepean Clinical School focusing on haematological malignancies and purinergic signaling. Collaborates with interdisciplinary teams in immunology, oncology, and structural biology.

• Medical Microbiology
• Tuberculosis Research
• Vaccine Development
• +۴ مورد دیگر

Professor Jamie Triccas is a Professor of Medical Microbiology and Theme Leader in the Infection, Immunity and Inflammation Theme at the University of Sydney’s School of Medical Sciences. He leads research programs in tuberculosis (TB) vaccine development, bacterial pathogenesis, and antimicrobial drug discovery. His work focuses on defining immunity to chronic bacterial pathogens like Mycobacterium tuberculosis, Pseudomonas aeruginosa, and Mycobacterium abscesses, alongside efforts to combat emerging threats such as SARS-CoV-2. He is part of the Sydney Infectious Diseases Institute and the Charles Perkins Centre, contributing to translational research with industry partners like Bharat Biotech and ExcellGene. His research interests span vaccine design, host-pathogen interactions, and drug discovery, with a focus on novel adjuvants and immunotherapies. Key achievements include advancing TB vaccine candidates through international consortia and developing a SARS-CoV-2 vaccine consortium supported by CEPI. He also leads NIH-funded studies on TB adjuvants and immune correlates. Recent studies highlight protective immune mechanisms against pulmonary infections, including IL-17A-driven T cell responses and lung-resident memory T cell generation. His team has discovered potent anti-tubercular compounds, such as bedaquiline analogues and metal-cyclam complexes, while patenting novel BCG-based vaccines (BCG-CYS). Current projects include assessing BCG efficacy against non-tuberculous mycobacteria in cystic fibrosis and investigating correlates of protection in SARS-CoV-2 immunity. Collaborations span global networks, emphasizing precision medicine in TB management and microbial therapy for cancer.

• Autoimmune Diseases
• Genetics
• Epigenetics
• +۳ مورد دیگر

Amr H. Sawalha is a Professor of Pediatrics and Medicine at the University of Pittsburgh and Director of the Rheumatology Division at UPMC Children's Hospital of Pittsburgh. He holds a dual role as Director of the Lupus Center of Excellence. His research focuses on genetic and epigenetic mechanisms underlying autoimmune diseases, combining genomic, epigenomic, and bioinformatics approaches with in vitro/in vivo functional studies. Education & Training: MD, Jordan University of Science and Technology (1998) Multidisciplinary Internship, Princess Basma Teaching Hospital (1998–1999) Internal Medicine Residency, University of Oklahoma Health Sciences Center (2000–2003) Rheumatology Fellowship, University of Michigan (2003–2005) Research Interests: His work centers on unraveling genetic/epigenetic contributions to systemic autoimmune diseases like lupus, scleroderma, and Behçet’s disease. Key areas include: Epigenetic regulation of immune pathways Genetic risk variants in Takayasu arteritis Immunometabolic dysregulation in lupus T cells Parent-of-origin DNA methylation effects Publications & Grants: Recent articles highlight SARS-CoV-2 interactions with autoimmune pathways and novel therapeutic targets like EZH2. Active grants include NIH-funded studies on lupus genetics (R01 AR070148) and epigenetic mechanisms in Takayasu arteritis. Awards: 2019 Henry Kunkel Young Investigator Award (ACR) 2014 American Society for Clinical Investigation Membership 2010 ACR/REF Rheumatology Investigator Award Labs & Affiliations: Based at the Rangos Research Center, he collaborates with multidisciplinary teams in immunology, genomics, and translational medicine. Active in professional societies including ACR, ASHI, and the Epigenetics Society.

• Precision Medicine
• Oncology
• Genetic Research
• +۳ مورد دیگر

Antonio Russo is a Full Professor of Precision Medicine at the University of Palermo, affiliated with the School of Medicine and Surgery and the Department of Medical Oncology. His research focuses on genetic mutations (e.g., BRCA), liquid biopsy, and biomarkers in oncology, particularly in ovarian, pancreatic, lung, and breast cancers. He leads studies on tumor immunology, therapeutic efficacy, and precision medicine strategies. He actively contributes to clinical trials, including those evaluating immunotherapy, targeted therapies, and novel biomarker applications. His administrative roles include managing relations with biomedical societies and patient associations. Research interests span molecular profiling of cancers, resistance mechanisms to therapies, and the role of circulating tumor DNA (ctDNA) in diagnosis. Notable areas include the prognostic value of tumor-infiltrating lymphocytes, cardiotoxicity of targeted drugs, and the clinical utility of exosomes. His work integrates translational research with clinical practice, emphasizing personalized treatment approaches. Publications highlight advancements in liquid biopsy, EGFR mutation detection, and PARP inhibitor efficacy. He collaborates on meta-analyses to optimize treatment protocols and address unmet clinical needs in metastatic cancers. His contributions aim to improve patient outcomes through innovative diagnostic and therapeutic strategies.

Cheryl Cameronمشاهده پروفایل

استادیار

• Systems Immunology
• Virology
• Autoimmunity
• +۷ مورد دیگر

Dr. Cheryl Cameron is an Assistant Professor in the Department of Nutrition at Case Western Reserve University's School of Medicine. Her research focuses on systems immunology approaches to study host responses to viral infections (HIV, SARS-CoV, influenza), vaccinations, autoimmunity (psoriasis, POTS), cardiovascular disease, and cancer. She joined the Department of Nutrition in 2019 as a translational researcher, integrating computational and experimental methods to identify therapeutic targets and improve personalized medicine strategies. Education: PhD in Virology from Western University (lab of Dr. Grant McFadden), followed by postdoctoral research at the University of Toronto on viral immunopathogenesis and host responses to respiratory viruses like SARS-CoV-1 and avian influenza. Her work highlights the metabolic and immune pathways linking viral infections to chronic conditions like cancer and cardiovascular disease. Research interests include: Systems immunology of viral infections and vaccines Host-pathogen interactions in chronic diseases Immune pathways dysregulated in HIV, cancer, and autoimmunity Role of diet/nutrition in modulating immune responses Development of predictive biomarkers for disease severity (e.g., SARS-CoV-2) Key findings include the discovery of viral immunomodulatory proteins (e.g., CD47 homologues in myxoma virus) and the identification of metabolic pathways impacted by diet and drug abuse. Her recent work on SARS-CoV-2 focuses on immune biomarkers and therapeutic targets for severe outcomes. Dr. Cameron collaborates on studies like the MAGMA trial (mineralocorticoid receptor antagonism in atherosclerosis) and offers research opportunities for students in both computational (big data analysis) and experimental (wet lab) domains.

Alvin H. Schmaierمشاهده پروفایل

استاد

• Vascular Biology
• Coagulation Pathways
• Thrombosis
• +۵ مورد دیگر

Alvin H. Schmaier, MD is a Professor in the Departments of Medicine and Pathology at Case Western Reserve University School of Medicine, and a member of the Molecular Oncology Program at the Case Comprehensive Cancer Center. His research focuses on vascular biology, particularly the interplay between the kallikrein-kinin system (KKS), renin-angiotensin system (RAS), and their roles in thrombosis, inflammation, and disease pathogenesis. Key areas of investigation include the activation mechanisms of plasma prekallikrein by endothelial prolylcarboxypeptidase, the protective role of bradykinin B2 receptor knockout mice against arterial thrombosis, and the development of thrombostatin compounds targeting thrombin activity. Recent work explores the role of these systems in malaria, SARS-CoV-2-induced kidney injury, and cancer-associated thrombosis. His research has uncovered novel pathways linking vascular inflammation, coagulation activation, and disease outcomes. Notably, his lab identified prolylcarboxypeptidase’s dual role in activating the KKS while degrading angiotensin II, highlighting its regulatory balance between vasoactive systems. He also investigates the pathophysiology of hereditary angioedema and the molecular genetics of thrombophilic traits like Fletcher and Fitzgerald syndromes. Scientific contributions include elucidating mechanisms of factor XII activation by bacterial lipopolysaccharides and cancer exosomes, and developing antithrombotic strategies with minimal bleeding risks. His work bridges basic science and clinical applications, targeting thrombosis prevention and treatment in complex conditions such as sepsis, cancer, and viral infections.

Werner Heldمشاهده پروفایل

استاد

• Immunology
• Cancer Immunotherapy
• Immune Responses
• +۷ مورد دیگر

Werner Held is a full professor at the UNIL Ludwig Center for Cancer Research within the Faculty of Biology and Medicine at the University of Lausanne. He has been a leading researcher in immunology since joining the institution, with a focus on the biology and function of killer immune cells. His appointment as full professor began on January 1, 2011, following a progression from assistant to associate member of the Ludwig Institute and an ad personam associate professorship at UNIL in 2006. Born: 1961, Emmental, Switzerland Doctorate: 1990, University of Bern, Immunology Postdoctoral Training: Ludwig Institute for Cancer Research (Epalinges), University of California, Berkeley Key Affiliation: UNIL Ludwig Center for Cancer Research Werner Held's research centers on understanding how the immune system, particularly natural killer (NK) cells and cytotoxic T lymphocytes, identifies and eliminates diseased cells such as cancer cells. His work aims to uncover the mechanisms by which these killer cells differentiate between healthy and abnormal cells and to determine the factors that limit their effectiveness in tumor environments. He investigates the potential to 're-educate' NK cells and improve the formation of cytotoxic T cell memory, which has significant implications for the development of advanced immunotherapies for cancer. His research lies at the intersection of fundamental immunology and translational oncology, contributing to new strategies in cancer treatment. Although specific publications are not listed, his body of work is focused on immune cell function, particularly within innate and adaptive immunity, with recurring themes in lymphocyte activation, tumor surveillance, and immune memory. His research trajectory emphasizes both basic science and its application to clinical challenges in oncology. Werner Held has been recognized for his contributions to science, most notably with the Leenaards Prize for the promotion of scientific research in 2006. Leenaards Prize for the promotion of scientific research (2006) Held secured a START grant from the Swiss National Science Foundation (SNSF) in 1997, which enabled him to build his research team and establish his independent laboratory in Lausanne. This early-career funding was instrumental in launching his academic career and fostering long-term research in immunology. There is no mention of additional grants or mentoring activities in the provided text, but his leadership in maintaining a research laboratory suggests sustained funding and team supervision. He has not been described as mentoring specific students, but his role as a full professor and lab head implies involvement in training junior scientists. Werner Held leads a research laboratory at the UNIL Ludwig Center for Cancer Research, where his team conducts fundamental studies on killer cells. The lab focuses on both NK cells and cytotoxic T lymphocytes, integrating molecular and cellular immunology approaches to explore immune responses against cancer. The research environment supports innovation in immunotherapy and fosters collaboration within the broader cancer research community at UNIL and affiliated institutions.

Jennifer S Carewمشاهده پروفایل

استاد

• Translational Oncology
• Hematological Malignancies
• Drug Resistance Mechanisms
• +۴ مورد دیگر

Jennifer S Carew, PhD, is a Professor in the Department of Medicine at the University of Arizona and Co-Director of the Hematological Malignancies Disease Team at the University of Arizona Cancer Center. Her translational research bridges mechanistic studies on experimental anticancer agents with early-phase clinical trials, focusing on overcoming drug resistance in hematological malignancies. PhD, University of Texas MD Anderson Cancer Center (mitochondrial defects in chronic lymphocytic leukemia) Postdoctoral Research, St. Jude Children’s Research Hospital (drug resistance in hematological malignancies) Dr. Carew's research emphasizes targeting regulators of protein turnover (e.g., ubiquitin-proteasome, autophagy) and epigenetic stability in cancers like multiple myeloma and leukemia. Her work includes developing lysosomal autophagy inhibitors (e.g., ROC-325), exploring oncolytic viruses, and combining novel agents with standard therapies to enhance efficacy. Her lab utilizes proteomic and pharmacodynamic analyses to validate drug mechanisms, such as NEDD8 inhibition (MLN4924) in leukemia, and investigates tumor suppressor roles of autophagy genes in myeloid neoplasms. Clinical translation includes investigator-initiated trials for hematological malignancies and advanced solid tumors. Dr. Carew holds multiple patents and has received institutional recognition from the American Cancer Society, Leukemia and Lymphoma Society, and Voelcker Foundation. She collaborates extensively with clinical teams to advance preclinical findings into therapeutic strategies, particularly for renal cell carcinoma, soft tissue sarcomas, and leukemias.

Mark A. Nelsonمشاهده پروفایل

استاد

• Cancer Biology
• Epigenetics
• Molecular Diagnostics
• +۳ مورد دیگر

Mark A. Nelson is a Professor in the Department of Pathology at the University of Arizona. His research focuses on inflammation and tumor progression/metastasis, racial disparities in cancer, and molecular diagnosis of cancer and genetic diseases. Key research themes include: Epigenetic markers for cancer detection (e.g., Sentinel-MPE liquid biopsy test) Immune interactions in tumor microenvironments Health equity and diagnostic innovation Current projects involve: Cell-free DNA methylation analysis for pleural effusion diagnostics Interdisciplinary studies on tumor-infiltrating lymphocytes Nanoparticle-based immunotherapy development He leads the Nelson Lab and has contributed to high-impact publications in Science , Nature Communications , and Mayo Clinic Proceedings .

• Pulmonary Medicine
• Critical Care
• Allergy and Immunology
• +۱۰ مورد دیگر

Neil Trivedi, MD , is a Professor in the School of Medicine at the University of California, San Francisco (UCSF) . His clinical and research expertise lies at the intersection of pulmonary medicine, critical care, and immunology, with a focus on mast cell biology and lung transplantation immunology. Dr. Trivedi completed his MD at UCLA and underwent residency and fellowship training in Internal Medicine and Pulmonary/Critical Care at UCSF. He has also completed training in diversity, equity, and inclusion, reflecting a commitment to equitable healthcare and research practices. His research interests include tryptase biology , lung allograft rejection , biomarker discovery , and genomic and proteomic analysis of mast cell disorders . He has led NIH- and VA-funded research projects investigating the role of mast cell proteases in disease and developing diagnostic tools for early detection of transplant rejection. Dr. Trivedi's publication history reveals a strong trend in translational immunology and pulmonary disease. His recent work focuses on genetically defined reference ranges for tryptase, the development of anti-tryptase therapies for severe asthma, and biomarker validation for lung nodule characterization and transplant rejection. These studies highlight a consistent effort to bridge molecular discovery with clinical diagnostics and therapeutics. He has not been awarded any scientific prizes listed in the provided text, though his work has been cited extensively and featured in high-impact journals such as Cell , Blood Advances , and Nature Genetics . Dr. Trivedi collaborates extensively with leading researchers, particularly Dr. George Caughey, and contributes to both basic science and clinical studies. His work on lung allograft rejection and mast cell disorders has implications for improving outcomes in transplant recipients and patients with severe allergic and inflammatory conditions. He is affiliated with research networks in tryptase, mast cells, and transplantation and has contributed to both primary research and review chapters in authoritative texts such as the Handbook of Proteolytic Enzymes .

• Inflammation
• Immune Regulation
• Neurodegenerative Diseases
• +۷ مورد دیگر

Sourav Ghosh, Ph.D., is a Professor in the Department of Neurology and Associate Professor in Pharmacology at Yale School of Medicine. He is co-director of a research laboratory with Dr. Carla Rothlin, focusing on the molecular regulation of inflammation. His work is affiliated with the Interdepartmental Neuroscience Program, Yale Cancer Center, and the Program for Neuroinflammation. Ph.D., University of Tennessee, Molecular Sciences (2000) M.Sc., University of Calcutta, Zoology (1992) Postdoctoral Fellowship, Salk Institute for Biological Studies Dr. Ghosh's research centers on the negative regulation of inflammation, particularly through pathways like TAM receptors (Tyro3, Axl, Mer), efferocytosis, and immune checkpoint mechanisms. His studies explore how dysregulation of these processes contributes to chronic inflammation, autoimmunity, cancer, and neurodegenerative diseases. He investigates the 'Goldilocks Principle' of immune response—ensuring inflammation is neither too weak nor too strong. His recent publications span top journals including Nature , Science , Cell , and Nature Immunology , with key themes in dendritic cell immunometabolism, senescence and efferocytosis, neuroinflammation, and epigenetic regulation in the nervous system. His work increasingly bridges immunology, neuroscience, and cancer biology. Cholesterol mobilization in dendritic cells and anti-tumor immunity Senescent cell suppression of efferocytosis in aging Retinal inflammation in Mertk-associated retinitis pigmentosa Stem cell regulation of tissue fitness via dead cell clearance Epigenetic control of PKMζ in brain function Dr. Ghosh has collaborated extensively with Dr. Carla Rothlin, Dr. Joseph Craft, and others across Yale. His lab contributes to interdisciplinary programs in neuroinflammation and cancer signaling. While specific grant details are not provided, his high-impact publications suggest significant research funding. He is actively involved in mentoring and training within the Yale Combined Program in the Biological and Biomedical Sciences (BBS). His laboratory is located at the Anlyan Center, 300 Cedar Street, New Haven, CT.

Benjamin G. Neelمشاهده پروفایل

استاد

• Cell Signaling
• Protein-Tyrosine Phosphatases
• Cancer Biology
• +۱۲ مورد دیگر

Benjamin G. Neel, MD, PhD, is a Professor in the Department of Medicine at NYU Grossman School of Medicine. His research is centered on cell signaling pathways, particularly those involving protein-tyrosine phosphatases such as SHP2, and their implications in cancer and genetic disorders like RASopathies. He leads an active research laboratory that integrates molecular biology, genomics, and translational models to uncover mechanisms of oncogenesis and therapy resistance. MD from Cornell University PhD from Rockefeller University Dr. Neel’s research focuses on the role of tyrosine phosphatases in signal transduction, especially the RAS-ERK pathway, and how dysregulation contributes to diseases including breast and ovarian cancers, lung cancer, and developmental syndromes. His lab employs advanced techniques such as CRISPR/Cas9 screens, proteomics, organoids, and genetically engineered mouse models (GEMMs) to dissect signaling networks and identify therapeutic vulnerabilities. His recent publications highlight key advances in understanding resistance to SHP2 inhibitors, hypoxia-induced cell death, neoantigen creation via covalent drugs, and tumor microenvironment remodeling. These works span high-impact journals like Nature , PNAS , and Cancer Cell , reflecting a strong trend toward integrating targeted therapy with immunomodulation and systems biology. Dr. Neel has mentored several successful scientists, including Dr. Wei Wei and Dr. Shengqing Gu, who have gone on to leadership roles in academia and cancer research. His lab fosters collaboration, notably with the Koide Lab, to develop novel immunotherapies. His scientific contributions have not been explicitly tied to named awards in the provided text, but his publication record and leadership position indicate national recognition. Through the Neel Lab, he continues to explore fundamental mechanisms in cancer signaling, with implications for drug development and precision oncology.

Kay L. Medinaمشاهده پروفایل

استاد

• B Cell Biology
• Hematopoiesis
• Leukemia
• +۷ مورد دیگر

Kay L. Medina, Ph.D., is a Professor of Immunology at Mayo Clinic in Rochester, Minnesota. Her research focuses on B lymphocyte biology in health, aging, and leukemogenesis, with a particular interest in molecular mechanisms involving Hoxa9 , miR-204 , and plasma cell niches . She leads studies on immune deficiency in chronic lymphocytic leukemia (CLL) and monoclonal B cell lymphocytosis (MBL).

Sima Portenمشاهده پروفایل

استادیار

• Urologic Oncology
• Genitourinary Cancer
• Bladder Cancer
• +۷ مورد دیگر

Dr. Sima Porten is a specialist in genitourinary cancers and a faculty member in the Department of Urology at the University of California San Francisco (UCSF) School of Medicine. She is part of the urologic oncology team at the UCSF Helen Diller Family Comprehensive Cancer Center, where she focuses on the diagnosis and treatment of bladder, kidney, and high-risk prostate cancers. Her research is centered on the biological and genetic mechanisms of urothelial carcinoma, aiming to develop personalized diagnostic tools and therapies. She has published extensively on topics including urine biomarkers, molecular imaging, health disparities, and treatment outcomes in bladder cancer. Her work integrates clinical practice, translational research, and health services to improve patient care. Dr. Porten’s recent publications reveal a strong focus on non-invasive diagnostics, molecular profiling, equity in cancer care, and innovative clinical trial design. Her research spans immunology, genetics, imaging, and patient-reported outcomes, reflecting a multidisciplinary approach to advancing bladder cancer management. Howard Hughes Medical Institute Research Scholar, NIH (2003) Alpha Omega Alpha Honor Society (2006) Julius R. Krevans Award for Clinical Excellence (2012) John Quale Travel Fellowship (2015) William R. Smart Distinguished Teaching Award (2017) Best Reviewer Award, Journal of Urology (2017) New Investigator Scholarship-Leadership Award, ALLIANCE Foundation (2019) Muriel Steele Society Honor (UCSF) Dr. Porten has been involved in major multi-institutional research collaborations and clinical trials, including SWOG S1605 and ECOG-ACRIN EA8212, contributing to national efforts in standardizing care and evaluating novel therapies. She has received grant support through awards such as the Faculty Learning and Development Fund and the ALLIANCE Foundation. While no direct mention of advising students is made, her leadership in research and teaching suggests a mentorship role within the department. She is actively engaged in professional societies including the American Urological Association and the Society of Urologic Oncology. Dr. Porten is affiliated with the UCSF Department of Urology and the Helen Diller Family Comprehensive Cancer Center, where she contributes to a multidisciplinary team advancing research and clinical care in urologic oncology.

Maria Virginia Baglioniمشاهده پروفایل

پژوهشگر

• Immunology
• T Cell Immunology
• Natural Killer T Cell
• +۴ مورد دیگر

Maria Virginia Baglioni is a Postdoctoral Researcher at the Department of Health Technology, Technical University of Denmark (DTU), specializing in Experimental & Translational Immunology with a focus on T-Cell Signaling and Development. Her research contributes to UN Sustainable Development Goals related to health and wellbeing. Dr. Baglioni's research expertise spans multiple areas of immunology, with particular focus on: T Cell Immunology and γδ T cells Natural Killer T Cell biology Barrier Immunity mechanisms Tumor Immunity and cancer immunology Immune Checkpoint Inhibitors and receptors Cellular Inhibitor of Apoptosis Proteins (CIAP1) Her recent publications demonstrate a strong focus on unconventional T cell populations, particularly examining how immune checkpoint receptors regulate γδ T cells, MAIT cells, and NKT cells in contexts of tumor immunity and barrier function. Her work on cIAP ubiquitin ligases reveals important mechanisms by which these proteins sustain type 3 γδ T cells and innate lymphoid cells during aging, promoting barrier immunity. Maria Virginia Baglioni is actively contributing to the field of immunology through her research at DTU's Department of Health Technology, where she works within the Experimental & Translational Immunology group focusing on T-Cell Signaling and Development.